. 2021 Jun 10;11:12277. doi: 10.1038/s41598-021-91021-9

Table 5.

Adjusted association of TANDEM size and drug-loading concentration with clinical outcomes and biochemical measures in patients with hepatocellular carcinoma.

Outcomes	TANDEM size (ref = 100 μm)	P-value	Doxorubicin loading (ref = Full loaded)	P-value
Outcomes	Estimate (95% CI)	P-value	Estimate (95% CI)	P-value
Better treatment response^a	0.99 (0.30, 3.31)	0.986	4.00 (1.06, 15.13)	0.041
Length of hospital stay (days)^b	− 0.84 (− 1.71, 0.02)	0.056	− 1.72 (− 2.77, -0.68)	0.001

^aLogistic regression was performed after adjusting for age, gender, CLIP stage, Child–Pugh Score, and total doxorubicin dosage. Odds ratio and 95% CI were presented.

^bLinear regression was performed after adjusting for age, gender, CLIP stage, Child–Pugh Score, and total doxorubicin dosage. The regression coefficients (β) indicated the difference in days between TANDEM size or doxorubicin-loading groups.